Literature DB >> 29136784

The alternation of autophagy/apoptosis in CD4+CD25+Foxp3+ Tregs on the developmental stages of atherosclerosis.

Yuling Tian1, Xiao Liang2, Yue Wu2.   

Abstract

Naturally regulatory T cells (Tregs) play a critical role in the regulation of T cell-mediated immune responses in atherosclerosis. However, the regulatory mechanism underlying Tregs upon long-term development of atherosclerosis remains unknown. Therefore, in this study, atherosclerotic model was induced in ApoE-/- mice by feeding fat-diet for 10 weeks. Quantification of atherosclerotic lesions was done by calculating the lesion size in the aortic sinus every 2 weeks. The lipid levels and inflammatory mediators were detected in serum sample. The populations of CD4+CD25+Foxp3+ Tregs were compared between ApoE-/- mice (ApoE-/-) and wild type C57BL/6 littermates (WT). The expression levels of autophagy and apoptosis signaling related regulators were determined by flow cytomery, RT-qPCR, and western blot assays in the CD4+CD25+Foxp3+ Tregs isolated from ApoE-/- and WT. We found that the sizes of plaque lesions in atherosclerotic ApoE-/- mice were larger than those in WT group during 10 weeks' detection (all P<0.05); Whereas, flow cytometry assay showed that the populations of CD4+CD25+Foxp3+ Tregs were significantly reduced in atherosclerotic ApoE-/- mice compared with those in corresponding WT group from the 4th weeks' detection (all P<0.05). The lipid accumulation and increased pro-inflammatory mediators were correlated with the developmental progression of atherosclerosis. Furthermore, compared to WT group, the functional properties of CD4+CD25+Foxp3+ Tregs from ApoE-/- mice showed a gradually decreased autophagic activity with aberrant expressions of LC3, Beclin1, ATG5, ATG7, p62 (all P<0.05), and a gradually increased apoptotic activity with abnormal expressions of cleaved caspase 3, Bim, Bcl-2 (all P<0.05) during the 10 weeks' detection period. Taken together, our data demonstrated that the population of CD4+CD25+Foxp3+ Tregs was reversely correlated with plaque forming in atherosclerotic ApoE-/- mice during atherosclerosis development. And the autophagy/apoptosis-dependent Tregs might play a crucial role for the maintenance of CD4 9+CD25+Foxp3+ Tregs survival during atherosclerosis progression.
Copyright © 2017 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  ApoE-/-; Apoptosis; Atherosclerosis; Autophagy; Foxp3; Naturally regulatory T cells

Mesh:

Substances:

Year:  2017        PMID: 29136784     DOI: 10.1016/j.biopha.2017.11.013

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Gene expression pattern of TCR repertoire and alteration expression of IL-17A gene of γδ T cells in patients with acute myocardial infarction.

Authors:  Xiao-Ming Chen; Tao Zhang; Dan Qiu; Jian-Yi Feng; Zhen-Yi Jin; Qiang Luo; Xin-Yu Wang; Xiu-Li Wu
Journal:  J Transl Med       Date:  2018-07-05       Impact factor: 5.531

2.  The effect of fingolimod on regulatory T cells in a mouse model of brain ischaemia.

Authors:  Kyle Malone; Andrea C Diaz Diaz; Jennifer A Shearer; Anne C Moore; Christian Waeber
Journal:  J Neuroinflammation       Date:  2021-01-30       Impact factor: 8.322

3.  Therapeutic Effect of Schistosoma japonicum Cystatin on Atherosclerotic Renal Damage.

Authors:  Huijuan Yang; Hongqi Li; Weidong Chen; Zhijie Mei; Yuan Yuan; Xiaoli Wang; Liang Chu; Yu Xu; Yan Sun; Dingru Li; Hongyu Gao; Bin Zhan; Huihui Li; Xiaodi Yang
Journal:  Front Cell Dev Biol       Date:  2021-11-25

Review 4.  Cell-Intrinsic Roles for Autophagy in Modulating CD4 T Cell Functions.

Authors:  Elise Jacquin; Lionel Apetoh
Journal:  Front Immunol       Date:  2018-05-09       Impact factor: 7.561

5.  Astragalus Oral Solution Ameliorates Allergic Asthma in Children by Regulating Relative Contents of CD4+CD25highCD127low Treg Cells.

Authors:  Wei Wang; Wei Jing; Qingbin Liu
Journal:  Front Pediatr       Date:  2018-09-20       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.